CM 2489

Drug Profile

CM 2489

Alternative Names: CCI; CM-2489; CRAC channel inhibitor - CalciMedica

Latest Information Update: 17 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CalciMedica
  • Class Antipsoriatics; Small molecules
  • Mechanism of Action Immunosuppressants; ORAI1 protein inhibitors; STIM1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Plaque psoriasis

Most Recent Events

  • 17 Nov 2016 Discontinued - Phase-I for Plaque psoriasis in USA (PO) before November 2016 (CalciMedica's website, November 2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Plaque-psoriasis in USA (PO)
  • 17 Feb 2011 Phase-I clinical trials in Plaque psoriasis (in volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top